Intentional and non-intentional non-adherence to medication amongst breast cancer patients

This study aimed to investigate the prevalence of and factors associated with non-adherence to medication amongst a sample of breast cancer patients. 131 women with stable disease were interviewed and completed standardised psychological measures. 55% of women reported non-adherence to medication frequently or occasionally, with younger women and those who disliked taking their medication being significantly less adherent (P = 0.015, P = 0.001). Women who deliberately omitted taking their tablets occasionally or frequently had significantly lower scores, indicative of a weaker influence, on 'internal' and 'powerful others' dimensions of health locus of control (P = 0.032, P = 0.009). Despite a life-threatening diagnosis, patients may not adhere to medication representing a potential missed opportunity for health gain and waste of resources. Furthermore, interpretation of clinical trial data may be misleading without adherence information. More research is needed to identify those at risk for non-adherence. If other routes of administration are available these options should be discussed with patients to maximise efficacy of therapy

Lγ1 x-ray Intensity Change in Proton Excited Nb Metal, Alloys and Compounds

開始ページ、終了ページ: 冊子体のページ付

Measurements of L x-Ray Chemical Influence in Chromium Compounds

開始ページ、終了ページ: 冊子体のページ付

Chemical Effects of L X-Ray Intensity Ratios in Niobium and Molybdenum Compounds by Elecron and Proton Bombardments

開始ページ、終了ページ: 冊子体のページ付

Associated Factors and Causes of Chronic Disease Medication Oversupply

Although medication oversupply results in waste of medications, triggers of medication oversupply remain unclear. This nationwide retrospective cohort study aimed to identify associated factors and causes of chronic disease medication oversupply in Japan by quantitative and qualitative analyses. Data of financial year 2019 from a large insurance claims database were used. Excess days, which represent medication oversupply in days, were calculated for each of the major five classes of chronic disease medications. For each class, the two cohorts were formed, consisting of individuals aged ≥55 years with either excessive oversupply or normal supply according to excess days. Oversupply-associated factors were subjected to quantitative analyses using logistic regression models, which included excessive oversupply vs. normal supply as an outcome variable. A qualitative analysis to identify causes of oversupply was performed by reviewing the medication history of 50 individuals randomly selected from each excessive oversupply cohort, and causes were classified into seven categories. Oversupply-associated factors in all classes were greater frequency of early supply (≥6 vs. &lt;3 times/10 supplies, odds ratio (OR) 5–9 for all classes), inpatient prescription (included vs. not included, OR 3–5), and higher number of concomitant ingredients (≥16 vs. 1–5 ingredients, OR 3–5). The most common category of causes for oversupply in all classes was the “early supply of medications prescribed by a single facility.” The factors and causes of oversupply might reflect the unique features, rules, and customs of Japan’s healthcare system. This finding might help in developing measures for reducing medication oversupply.</p

Improvement in Background Reduction for X-Ray Spectrum obtained with Crystal Spectrometer

開始ページ、終了ページ: 冊子体のページ付

Chemical Analysis of Impurity Boron Atoms in Diamond Using Soft X-ray Emission Spectroscopy

To analyze the local structure and/or chemical states of boron atoms in boron-doped diamond, which can be synthesized by the microwave plasma-assisted chemical vapor deposition method (CVD-B-diamond) and the temperature gradient method at high pressure and high temperature (HPT-B-diamond), we measured the soft X-ray emission spectra in the CK and BK regions of B-diamonds using synchrotron radiation at the Advanced Light Source (ALS). X-ray spectral analyses using the fingerprint method and molecular orbital calculations confirm that boron atoms in CVD-B-diamond substitute for carbon atoms in the diamond lattice to form covalent B-C bonds, while boron atoms in HPT-B-diamond react with the impurity nitrogen atoms to form hexagonal boron nitride. This suggests that the high purity diamond without nitrogen impurities is necessary to synthesize p-type B-diamond semiconductors

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis

BackgroundThe effectiveness of a dexamethasone-sparing strategy in the treatment of breast cancer with anthracycline-cyclophosphamide therapy when combined with first-generation 5-HT3 receptor antagonists (RAs) and neurokinin-1 RAs is unclear. This is attributable to a lack of evidence from direct comparison of multiple doses of DEX to a single dose of DEX in combination with first-generation 5-HT3 RAs in anthracycline-cyclophosphamide therapy. Our goal was to clarify the impact of dexamethasone-sparing strategies that involve both first-generation 5-HT3 RAs and palonosetron when combined with neurokinin-1 RAs, using a network meta-analysis.Materials and methodsA literature search was conducted on PubMed/Medline for articles published up to July 4, 2023. We included randomized controlled trials which assessed the efficacy of antiemetic regimens which combined 5-HT3 RAs and dexamethasone, with or without neurokinin-1 RAs, for the initial dose in anthracycline-cyclophosphamide therapy for patients with breast cancer. The primary outcome was the proportion of patients achieving a complete response during the delayed phase (CR-DP).ResultsThe difference in the proportion of patients achieving CR-DP between multiple and single doses of dexamethasone was 0.1% (95%CI: -12.4 to 12.5) with palonosetron and neurokinin-1 RAs, compared to 5.3% (95%CI: -13.4 to 23.0) with a single dose of a first-generation 5-HT3 receptor antagonist. Additionally, the difference was 12.7% (95% CI: -2.8 to 28.2) when comparing palonosetron against first-generation 5-HT3 RAs in combination with a single dose of dexamethasone and neurokinin-1 RAs.ConclusionPalonosetron is recommended rather than a single dose of first-generation 5-HT3 RAs in dexamethasone-sparing strategies for anthracycline-cyclophosphamide therapy